Spike Protein News and Research

RSS

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

A new study reports the underlying basis of increased transmissibility in the N501Y UK variant and provides reassuring data on the efficacy of the Pfizer vaccine and Eli Lilly monoclonal antibodies in neutralizing it.

4 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically.

4 Feb 2021

Study shows how SARS-CoV-2 evades immune responses

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the University of Pittsburgh School of Medicine.

4 Feb 2021

SARS-CoV-2 has developed worrying new mutation in UK

Over the past few months, surging cases have been reported due to new fast-spreading variants. Now, Public Health England (PHE) investigates cases of COVID-19 with worrying new genetic changes. The E484K mutation, which could allow SARS-CoV-2 escape antibody protection, was seen in a small group of cases in some regions of the country.

4 Feb 2021

Predicting future mamalian hosts of SARS-CoV-2

Researchers at the Beijing Computational Science Research Center and Peking University analyzed sequences of the angiotensin-converting enzyme 2 (ACE2) proteins from 16 mammals and predicted the structures of ACE2- receptor-binding domain (RBD) complexes.

4 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

A new preprint examines Long COVID-19, aiming to identify the underlying immunologic status in such patients.

3 Feb 2021

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

The SARS-CoV-2, the new coronavirus behind the current pandemic, infects humans by binding its surface-exposed spike proteins to ACE2 receptors exposed on the cell membranes.

3 Feb 2021

Key variants help explain the differences between viruses that cause COVID-19 and SARS

An effort led by Lin Li, Ph.D., assistant professor of physics at The University of Texas at El Paso, in collaboration with students and faculty from Howard University, has identified key variants that help explain the differences between the viruses that cause COVID-19 and Severe Acute Respiratory Syndrome (SARS).

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection

The findings reveal that healthcare workers previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop significantly higher antibody titers in response to a single dose of COVID-19 vaccine, as compared to healthcare workers without prior SARS-CoV-s infection. The study is currently available on the medRxiv* preprint server.

2 Feb 2021

Highly conserved neutralizing epitope identified on SARS-CoV-2 spike protein

A recent study conducted at the University of Texas at Austin, USA, has identified a highly conserved neutralizing antibody binding site on the spike S2 domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study findings might help develop novel spike-targeting antibodies for widespread protection. The study is currently available on the bioRxiv preprint server.

2 Feb 2021

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

A test that detects antibodies to the novel coronavirus in 10 minutes and costs only a fifth of the market average has been developed by researchers at the University of São Paulo's São Carlos Chemistry Institute and Brazilian startup Biolinker, with São Paulo Research Foundation - FAPESP's support.

2 Feb 2021

What is the structure and function of SARS-CoV-2’s D614G spike mutation?

A team of researchers use a computational approach to integrate available data D614G SARS-CoV-2 spike mutation, exploring its structure and molecular mechanisms.

2 Feb 2021

Zinc supplementation bolsters repurposed antivirals against SARS-CoV-2

A new preprint reports the efficacy of two repurposed drugs that could be useful against SARS-CoV-2 when supplemented with zinc.

2 Feb 2021

Pfizer-BioNTech vaccine shows promise against new SARS-CoV-2 variants

A team of researchers in the U.S. studied the Pfizer-BioNTech vaccine candidate - currently being rolled out in many parts of the world to high-risk individuals - to see if it still holds up against mutant strains of the virus and yielded encouraging results.

2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Spike Protein News and Research

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

Study shows how SARS-CoV-2 evades immune responses

SARS-CoV-2 has developed worrying new mutation in UK

Predicting future mamalian hosts of SARS-CoV-2

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

Key variants help explain the differences between viruses that cause COVID-19 and SARS

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection

Highly conserved neutralizing epitope identified on SARS-CoV-2 spike protein

Researchers develop rapid COVID-19 diagnostic test affordable for low-income families

What is the structure and function of SARS-CoV-2’s D614G spike mutation?

Zinc supplementation bolsters repurposed antivirals against SARS-CoV-2

Pfizer-BioNTech vaccine shows promise against new SARS-CoV-2 variants

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News